Production (Stage)
Neumora Therapeutics, Inc.
NMRA
$1.02
$0.209925.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -26.57% | 45.90% | -36.81% | -52.30% | -50.80% |
| Total Depreciation and Amortization | -0.63% | -5.42% | -9.83% | -6.43% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.01% | -86.22% | 51.00% | 406.66% | 231.46% |
| Change in Net Operating Assets | -114.62% | 89.66% | 2,567.23% | -277.22% | 1,062.14% |
| Cash from Operations | -38.40% | 2.14% | 29.91% | -81.03% | -30.01% |
| Capital Expenditure | -- | 1,861.36% | 100.00% | -- | -2,052.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 129.59% | -825.71% | 558.18% | -11.72% | -5,330.49% |
| Cash from Investing | 129.44% | -822.37% | 559.20% | -11.72% | -5,424.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 4,427.43% | -99.25% | 556.93% | 206.48% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 127.44% | 92.14% | -- | -- |
| Cash from Financing | -- | 3,337.63% | -99.34% | 808.90% | 1,726.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.00% | -249.23% | -39.91% | -384.80% | -534.44% |